Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy

Journal of Surgical Oncology

Volumn 73, Issue 1, 2000, Pages 12-16

  Barişta, Ibrahim ^a   Tekuzman, Gülten ^a   Yalçin, Şuayib ^a   Güllü, Ibrahim ^a   Güler, Nilüfer ^a   Özişik, Yavuz ^a   Kars, Ayşe ^a   Çelik, Ismail ^a   Türker, Alev ^a   Altundaǧ, Kadri ^a   Zengin, Nurullah ^a   Üner, Ayşegül ^a   Baltali, Eşmen ^a   Firat, Dinçer ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Doxorubicin; Ifosfamide; Soft tissue sarcoma

Indexed keywords

DOXORUBICIN; IFOSFAMIDE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SOFT TISSUE SARCOMA;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; FEMALE; FEVER; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MESNA; MIDDLE AGED; NEUTROPENIA; PROTECTIVE AGENTS; REMISSION INDUCTION; SARCOMA; SURVIVAL RATE;

EID: 0343049058     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(200001)73:1<12::AID-JSO4>3.0.CO;2-K     Document Type: Article

References (26)

1. Borden EC, Amato DA, Rosenbaum C, et al.: Randomized comparison of three Adriamycin regimens for metastatic soft tissue carcinomas. J Clin Oncol 1987;5:840-850.
2. O'Bryan RM, Luce JK, Talley RW, et al.: Phase II evaluation of adriamycin in human neoplasia. Cancer 1973;32:1-8.
3. Antman KH, Ryan L, Elias A, et al.: Response to ifosfamide and mesna: 124 previously treated patients with metastatic unresectable sarcoma. J Clin Oncol 1989;7:126-131.
4. Stuart-Harris R, Harper PG, Kaye SB, Wiltshaw E: High dose infusion with mesna in advanced soft tissue sarcoma. Cancer Treat Rev 1983;10(Suppl. A): 163-164.
5. Keohan ML, Taub RN: Chemotherapy for advanced sarcoma: Therapeutic decisions and modalities. Semin Oncol 1997;24:572-579.
6. Buesa JM, López-Pousa A, Martin J, et al.: Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol 1998;9:871-876.
7. O'Byrne K, Steward WP: The role of chemotherapy in the treatment of adult soft tissue sarcomas. Oncology 1999;56:13-23.
8. Russell WO, Cohen J, Enzinger F, et al.: A clinical and pathological staging system for soft tissue sarcomas. Cancer 1977;40: 1562-1570.
9. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48. Geneva: World Health Organization, 1979.
10. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
11. Yang JC, Rosenberg SA, Glatstein EJ, Antman KH: Sarcomas of soft tissues. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer Principles and Practice of Oncology, 4th ed. Philadelphia: Lippincott, 1993:1436-1488.
12. Suit HD, Russell WO, Martin RG: Sarcoma of the soft tissue: clinical and histopathological parameters and response to treatment. Cancer 1975;35:1478-1483.
13. Benjamin RS, Legha SS, Patel S, Nicaise C: Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol 1993; 31(Suppl. 2):S174-S179.
14. Antman KH: Chemotherapy of advanced sarcomas of bone and soft tissue. Semin Oncol 1992;19(Suppl. 12):13-22.
15. Lind MJ, Margison JM, Cerny T, et al.: The effect of age on pharmacokinetics of ifosfamide. Br J Clin Pharmacol 1990;30: 140-143.
16. Schütte J, Mouridsen HT, Stewart W, et al.: Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. Eur J Cancer 1990;26:558-561.
17. Santoro A, Tursz T, Mouridsen H, et al.: Doxorubicin versus CyVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13: 1537-1545.
18. Antman K, Crowley J, Balcerzak SP, et al.: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-1285.
19. Güllü I, Yalçin Ş, Tekuzman G, et al.: High-dose ifosfamide by infusion with mesna in advanced refractory sarcomas. Cancer Invest 1996;14:239-242.
20. Yalçin Ş, Güllü IH, Barişta I, et al.: Treatment of advanced refractory sarcomas with ifosfamide and etoposide combination chemotherapy. Cancer Invest 1998;16:297-302.
21. Mansi JL, Fisher C, Wiltshaw E, et al.: A phase I-II study of ifosfamide in combination with Adriamycin in the treatment of adult soft tissue sarcoma. Eur J Cancer Clin Oncol 1988;24:1439-1443.
22. Schütte J, Kellner R, Seeber S: Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. Cancer Chemother Pharmacol 1993;31:S194-S198.
23. Loehrer PJ, Sledge GW Jr, Nicaise C, et al.: Ifosfamide plus doxorubicin in metastatic adult sarcomas. A multi-institutional phase II trial. J Clin Oncol 1989;7:1655-1659.
24. Weh HJ, Zügel M, Wingberg D, et al.: Chemotherapy of metastatic soft tissue sarcoma with a combination of Adriamycin and DTIC or Adriamycin and ifosfamide. Onkologie 1990;13:448-452.
25. Steward WP, Verweij J, Somers R, et al.: Granulocytemacrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993;11:15-21.
26. Edmonson JH, Ryan LM, Blum RH, et al.: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-1275.